Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical utility of exemestane in the treatment of breast cancer.
Zucchini G, Geuna E, Milani A, Aversa C, Martinello R, Montemurro F. Zucchini G, et al. Among authors: montemurro f. Int J Womens Health. 2015 May 27;7:551-63. doi: 10.2147/IJWH.S69475. eCollection 2015. Int J Womens Health. 2015. PMID: 26064072 Free PMC article. Review.
Underuse of anthracyclines in women with HER-2+ advanced breast cancer.
Montemurro F, Rossi V, Nolè F, Redana S, Donadio M, Martinello R, Verri E, Valabrega G, Rocca MC, Jacomuzzi ME, Viale G, Sapino A, Aglietta M. Montemurro F, et al. Oncologist. 2010;15(7):665-72. doi: 10.1634/theoncologist.2010-0016. Epub 2010 Jun 24. Oncologist. 2010. PMID: 20576644 Free PMC article.
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F. Valabrega G, et al. Among authors: montemurro f. Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9. Breast Cancer Res Treat. 2011. PMID: 21153051
Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer.
Rossi V, Sarotto I, Maggiorotto F, Berchialla P, Kubatzki F, Tomasi N, Redana S, Martinello R, Valabrega G, Aglietta M, Ponzone R, Montemurro F. Rossi V, et al. Among authors: montemurro f. Oncologist. 2012;17(11):1418-25. doi: 10.1634/theoncologist.2012-0194. Epub 2012 Sep 4. Oncologist. 2012. PMID: 22951668 Free PMC article.
256 results